Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 13, 2026
Feasibility and acceptability of an electronic decision aid for genetic testing in ovarian and pancreatic cancer patients.
Journal: Research connections
Published: January 19, 2026
Exposure-Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial.
Journal: Clinical pharmacology in drug development
Published: December 12, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.
Journal: Nature communications
Published: July 12, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.
Journal: JCO precision oncology
Published: April 10, 2025
Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers.
Journal: Signal transduction and targeted therapy
Published: March 16, 2025
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 28, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
Journal: Gynecologic oncology
Published: February 22, 2025
Oxidation of retromer complex controls mitochondrial translation.
Journal: Nature
Published: June 04, 2024
Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY.
Journal: British journal of clinical pharmacology
Published: April 22, 2024
Identification of chemotherapy targets reveals a nucleus-to-mitochondria ROS sensing pathway.
Journal: bioRxiv : the preprint server for biology
Published: March 22, 2023
Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors.
Journal: Journal of the National Cancer Institute
Published: January 09, 2023
Last Updated: 09/26/2026